Sensus Healthcare vs Vivos Therapeutics
SRTS and VVOS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SRTS and VVOS compare
Sensus Healthcare is the larger company, worth 19 times as much as Vivos Therapeutics ($38.3M against $2.0M).
Vivos Therapeutics grew revenue faster over the last twelve months (45.2% versus −53.4% for Sensus Healthcare).
Sensus Healthcare keeps more of each dollar of sales as profit, with a net margin of −88.5% compared with −122% at Vivos Therapeutics.
Sensus Healthcare scores higher on the StockData Score (9 against 3 for Vivos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SRTS | VVOS |
|---|---|---|
| Size and price | ||
| Market cap | $38.3M | $2.0M |
| Share price | $2.33 | $0.098 |
| Change, 1 year | −49.5% | −96.1% |
| Change, 5 years | −58.1% | −99.9% |
| Beta (5Y) | 1.13 | 1.45 |
| Employees | 60 | 268 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.2× | 0.1× (better) |
| P/B | 1.0× | – |
| FCF yield | −18.2% (better) | −964% |
| Fair value | $4.07 | – |
| Margin of safety | 42.9% | – |
| Growth | ||
| Revenue growth (TTM) | −53.4% | 45.2% (better) |
| Revenue growth, 5Y average | 23.5% (better) | 5.9% |
| Profitability | ||
| Gross margin | 36.4% | 61.9% (better) |
| Operating margin | −75.7% (better) | −108% |
| Net margin | −88.5% (better) | −122% |
| FCF margin | −39.8% (better) | −91.0% |
| Return on equity | −34.8% (better) | −6629% |
| Return on invested capital | −40.6% (better) | −335% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −6.4× |
| Current ratio | 8.71 (better) | 0.21 |
| Altman Z-score | 5.37 (better) | −11.01 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −297% |
| Shareholder yield | 0.00% (better) | −297% |
| Ownership | ||
| Held by institutions | 22.2% | 2.6% |
| Held by insiders | 13.3% | 30.4% |
| Insider net buying, 12 months | $576K | $1.8M (better) |
| Short interest, % of float | 1.6% | 21.9% |
Go deeper
- SRTS stock overview
- SRTS income statement
- SRTS valuation and score
- VVOS stock overview
- VVOS income statement
- VVOS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.